STOCK TITAN

Vir Biotechnology, Inc. - VIR STOCK NEWS

Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.

Vir Biotechnology, Inc. (VIR) pioneers immunology solutions targeting complex infectious diseases through innovative platforms including antibody therapies, T cell engineering, and siRNA technology. This dedicated news hub provides investors and industry stakeholders with timely updates on clinical developments, strategic partnerships, and regulatory milestones.

Access authoritative updates on VIR's research pipeline, financial performance announcements, and scientific breakthroughs in infectious disease management. Our curated collection ensures transparent access to press releases spanning clinical trial progress, collaborative initiatives, and patent filings.

Key updates include advancements in hepatitis B/HIV therapies, influenza A research, and platform technology licensing agreements. Bookmark this page to efficiently monitor VIR's contributions to biotechnology and its evolving position in global health innovation.

Rhea-AI Summary

Vir Biotechnology announced the appointment of Jeffrey Hatfield to its Board of Directors. Hatfield brings over 30 years of experience in the pharmaceutical industry, having previously led Vitae Pharmaceuticals and held executive positions at Bristol Myers Squibb. His expertise in commercial programs and platform-based companies is expected to drive Vir's growth, especially as the company tackles serious infectious diseases, including COVID-19. Hatfield's past successes, including the $640 million acquisition of Vitae by Allergan, position him as a valuable asset for Vir's future endeavors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.24%
Tags
management
-
Rhea-AI Summary

Vir Biotechnology reported third-quarter financial results for the period ending September 30, 2020, with total revenues increasing to $1.9 million from $1.4 million year-over-year, driven by research activities under HIV and TB grants. However, research and development expenses surged to $70.7 million, leading to a net loss of $84.6 million, or $0.67 per share, compared to a loss of $48.3 million, or $4.60 per share, in Q3 2019. The company is advancing its SARS-CoV-2 programs, including the Phase 3 trial of VIR-7831, expecting initial results in January 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.85%
Tags
-
Rhea-AI Summary

Vir Biotechnology has published a comprehensive study on the SARS-CoV-2 receptor binding motif (RBM), revealing high mutation rates that enhance immune evasion. Notably, the N439K variant has shown resistance to several monoclonal antibodies, indicating ongoing challenges in vaccine development. Analyzing over 130,000 viral sequences, the research emphasizes the necessity for continuous monitoring of emerging variants. The findings suggest that VIR-7831 aims to target conserved epitopes to mitigate resistance, enhancing long-term immunity against COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.58%
Tags
none
Rhea-AI Summary

Vir Biotechnology, Inc. (Nasdaq: VIR) will announce its third-quarter financial results for the period ended September 30, 2020, on November 10, 2020. The corporate update will be released after market close and made available on their website. Vir focuses on treating serious infectious diseases using innovative immunology technologies. Their development pipeline includes candidates for various diseases such as hepatitis B, influenza A, SARS-CoV-2, HIV, and tuberculosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.87%
Tags
-
Rhea-AI Summary

Vir Biotechnology has released data on VIR-2482, a monoclonal antibody aimed at preventing influenza A. The preclinical and Phase 1 studies reveal promising results, including broad neutralizing capability against historical strains and a prolonged half-life that supports potential once-per-season dosing. Notably, elderly patients with comorbidities are at high risk for severe influenza complications, with hospitalization rates between 19%-44% and associated costs of $4,122-$8,181 per patient. This underscores the need for effective prevention strategies, which VIR-2482 may fulfill.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
none
-
Rhea-AI Summary

Vir Biotechnology and Alnylam Pharmaceuticals will participate in a virtual fireside chat at the H.C. Wainwright Hepatitis B Virus Mini-Conference on October 20, 2020, at 9:30 am PT/12:30 pm ET. Phil Pang, M.D., Chief Medical Officer of Vir, and Vasant Jadhav, Ph.D., Vice President of Research at Alnylam, will lead the discussion. The event will be accessible via live webcast on both companies' investor websites, with archives available for 30 days post-event.

Vir focuses on treating serious infectious diseases, while Alnylam specializes in RNA interference therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
conferences
Rhea-AI Summary

Vir Biotechnology has published promising preclinical research demonstrating a new mechanism to enhance monoclonal antibodies' efficacy against viral infections. The study highlights how engineered antibodies can induce protective T-cell responses by engaging specific Fc receptors on dendritic cells. This therapeutic method, previously used for oncologic treatments, may broaden to various infectious diseases. Notably, Vir is advancing clinical development for two engineered antibodies: VIR-3434 for chronic hepatitis B and VIR-7832 for SARS-CoV-2, potentially revolutionizing treatment approaches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
none
-
Rhea-AI Summary

Vir Biotechnology and GlaxoSmithKline announced the transition of the COMET-ICE study to Phase 3 for evaluating VIR-7831, a monoclonal antibody targeting COVID-19 in high-risk patients. Following a favorable safety review on September 30, 2020, the study will expand globally with results anticipated for the primary endpoint by January 2021. The trial involves approximately 1,300 non-hospitalized patients and aims to assess the efficacy and safety of VIR-7831. Further trials for both hospitalized patients and preventative treatments are also planned.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.11%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Vir Biotechnology has published a significant analysis of antibody responses to SARS-CoV-2, involving nearly 650 infected patients. The study reveals that antibody magnitude correlates with disease severity, with hospitalized patients showing higher levels. Key findings highlight a rapid decline in natural antibody response and identify the receptor binding domain (RBD) as the primary target for neutralizing antibodies. Collaborating with GSK, Vir is advancing therapies like VIR-7831 for early COVID-19 treatment, reflecting progress in vaccine and therapeutic design.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.44%
Tags
none
Rhea-AI Summary

Vir Biotechnology will have its chief medical officer, Phil Pang, M.D., Ph.D., present at the Cantor Global Virtual Healthcare Conference on September 15, 2020, at 8:20 am PT / 11:20 am ET.

Investors can access a live webcast of the presentation through the Investors section of the Vir website, which will be archived for 30 days thereafter. The company continues to utilize its Investors page for material non-public information disclosures, complying with Regulation FD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.26%
Tags
conferences
Vir Biotechnology, Inc.

Nasdaq:VIR

VIR Rankings

VIR Stock Data

759.35M
101.72M
12.01%
76.71%
5.66%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN FRANCISCO